We previously showed that a vaccine combining interleukin 12 and allogeneic p185neu-positive mammary carcinoma cells completely prevented multifocal mammary carcinogenesis ih HER-2/neu transgenic mice. To identify the molecular events responsible for effective tumor prevention and to define the tumor gene expression signature, we used microarrays to analyze the expression profile of mammary tissue of untreated transgenic mice and of vaccine-treated, tumor-free mice at different time points. Mammary tissue from vaccinated mice displayed a gene expression profile different from that of untreated, tumor-bearing mice but similar to that of normal/hyperplastic mammary gland. Comparison of treated and untreated-mice at 15 weeks of age revealed up-regulation of genes encoding antibodies, chemokines, γ-interferon- induced genes and inflammatory molecules, and down-regulation of early genes induced by tumor development The gene expression signature of HER-2/neu-transformed tumor cells showed modulation of genes promoting proliferation, angiogenesis, migration, invasion, and metastasis and inhibiting apoptosis and immune response. Meta-analysis of microarray data on human breast cancer showed that the signature of tumors arising in murine HER-2/neu transgenic model correctly classified human HER-2/neu-expressing tumors and normal breast tissue. Moreover murine and human HER-2/neu-positive tumors share the signature of basal-like breast cancers. This gene expression analysis reveals the immune events associated with prevention of tumor development and shows that HER-2/neu transgenic mice represent a good model of a poor-prognosis group of human breast tumors.
|Number of pages||12|
|Journal||American Journal of Pathology|
|Publication status||Published - Apr 2005|
ASJC Scopus subject areas
- Pathology and Forensic Medicine